SwastiChemEx: Dr Reddy's Laboratories

Dr Reddy's Laboratories (DRL), the second largest pharmaceutical company in India after Sun Pharmaceutical Industries, is surging ahead with strong domestic sales as well as exports to overseas markets with clear focus on research and development, expansion, alliances and new products. After good financial performance in the first quarter ended June 2015 as well as for full year 2014-15, DRL scrip moved up strongly and touched its yearly high level at Rs.4084.95 with full market capitalization of over Rs.68,550 crore on the BSE. With 25.5 per cent equity holding with promoters and 37.8 per cent by foreign institutional investors, DRL share of Rs.5 each is crossed milestone of Rs.4000 on July 31, 2015.

Considering the changing healthcare scenario, DRL has changed its corporate brand identity recently with new logo which is an expression of empathy and dynamism. The new logo keeps patients at the center of everything that DRL does. The objective of the re-branding exercise is to derive a unifying, patient-centric approach, to meet new and daunting challenges that patients are facing.

DRL has posted satisfactory financial performance during the first quarter ended June 2015. Its consolidated net profit went up by 13.7 per cent to Rs.626 crore from Rs.550 crore in the corresponding period of last year. EBITDA improved by 12 per cent to Rs.990 crore. Its consolidated net sales increased by 6.8 per cent to Rs.3,758 crore from Rs.3,518 crore. EPS improved to Rs.36.71 from Rs.32.34 in the last period.

Dr Reddy's Laboratories, second largest Indian pharma major after Sun Pharmaceuticals with net sales of Rs. 13,200 crore plus, has received setback during the third quarter ended December 2014 on account of higher R&D expenditure and higher tax provisions. The company's consolidated net profit declined by 7.1 per cent to Rs. 575 crore from Rs. 619 crore in the corresponding period of last year despite higher finance income of Rs. 101 crore as compared to Rs. 1.47 crore in the previous period.

Though the overall performance was under pressure, DRL scrip moved up smartly by over 4 per cent or over Rs. 130 in the afternoon session on BSE to Rs. 3,366.

The consolidated net sales improved by 8.7 per cent to Rs. 3,843 crore from Rs. 3,534 crore in the similar quarter of last year. Its sales of global generic went up by 7.8 per cent to Rs. 3,169 crore from Rs. 2,940 crore and that of pharmaceutical services & active ingredients (PSAI) improved by 22.1 per cent to Rs. 799 crore from Rs. 654 crore. However, the sales from proprietary products declined by 18.8 per cent to Rs. 39 crore from Rs. 48 crore and other sales declined by 40.2 per cent to Rs. 24 crore from Rs. 40 crore.

The revenues from North America increased by 4 per cent to Rs. 1680 crore. The company launch limited competition products namely decitabine, azacitidine and divalproex sodium ER and expanding market share of key molecules namely ziprasidone, amlodipine-atorvastatin and sumatriptan auto injector. It launch 6 new products during the quarter ended December 2014. It filed 2 ANDas and 68 ANDAs are pending for approval with US FDA. Out of this 13 are 'First to File' status.

NEW DELHI: Torrent Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing securities and will seek shareholders' nod in this regard.

The proposals were cleared by the company's board during its meeting today.

With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.

The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualif ..

Torrent Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing securities and will seek shareholders' nod in this regard.

The proposals were cleared by the company's board during its meeting today.

With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.

The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..

Monday, 3 August 2015

Dr Reddy's crossed Rs.4000 mark on BSE with 86% income from exports, new launches

Thursday, 29 January 2015

Dr Reddy's Laboratories posts lower net profit at Rs. 575 cr in Q3